01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
16:15 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination with inhibition of MC-1 could help treat STK11-deficient lung cancer. In a human STK11-deficient lung cancer cell line, the...
18:22 , Apr 13, 2018 |  BC Extra  |  Preclinical News

NCI identifies new lymphoma subtypes

A New England Journal of Medicine paper out of NIH's National Cancer Institute revealed new subtypes of diffuse large B cell lymphomas (DLBCL) that could lead to more targeted therapeutic strategies. The report adds to...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Mar 12, 2015 |  BC Innovations  |  Targets & Mechanisms

TBK1 and beyond

Biogen Idec Inc. 's partnership with Columbia University and the HudsonAlpha Institute for Biotechnology has yielded a new target in ALS - TBK1 - that provides a link between autophagy, neuroinflammation and the pathology of...
08:00 , Jan 8, 2015 |  BC Innovations  |  Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer TANK-binding kinase 1 (TBK1); inhibitor of k-light polypeptide gene enhanced in B cells kinase-e (IKBKE; IKK-i); HER2 (EGFR2; ErbB2; neu) In vitro and...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer TANK-binding kinase 1 (TBK1); inhibitor of k-light polypeptide gene enhancer in B cells kinase-e (IKBKE; IKK-i); Janus kinase-1 (JAK-1); JAK-2; K-Ras (KRAS) Cell...
08:00 , Feb 3, 2014 |  BioCentury  |  Emerging Company Profile

ImStar: Neuronal pacifier

ImStar Therapeutics Inc. is using new discoveries about the physiopathology of amyotrophic lateral sclerosis to develop small molecules that block a key kinase interaction leading to immune-related neuroinflammation. The company hopes to have preclinical proof-of-concept...